Frontline therapy combining with intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome in pediatric relapsed B-ALL receiving pCAR-19B
Saved in:
Main Authors: | Lu Cao, Shaoyan Hu, Zhengjiang Bai, Shuiyan Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-06-01
|
Series: | EJC Paediatric Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772610X25000881 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
by: Evgenii Shumilov, et al.
Published: (2025-08-01) -
Use of locally produced anti-CD19 CAR-T cells in the treatment of relapsed/refractory B-cell lymphomas in adults
by: N. E. Konoplya, et al.
Published: (2023-09-01) -
Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis
by: Alexander Biederstädt, et al.
Published: (2025-07-01) -
Adding dexamethasone to intrathecal bupivacaine 0.5%; comparing the anesthetic ability with bupivacaine 0.5% alone among cesarean section patients
by: Seyed Mohammad Nasirodin Tabatabaei, et al.
Published: (2022-06-01)